WS #13450
Holding: newest synthesis is 97d 12h old
Eli Lilly Q2 revenue +48% to $23B, EPS $8.38 vs $8.38 est, raised FY26 guidance on strong Mounjaro/Zepbound demand, but M&A spending trims EPS outlook.
Eli Lilly GLP-1 earnings beat
Eli Lilly Q2 revenue +48% to $23B, EPS $8.38 vs $8.38 est, raised FY26 guidance on strong Mounjaro/Zepbound demand, but M&A spending trims EPS outlook.